A different study presented at the 2025 ASCO Annual Meeting showed that one specific diet may benefit people with colon ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) is one of the best penny stocks under $1 to buy now. Earlier in June, Mersana ...

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Some treatments for rheumatoid arthritis could increase cancer risk. One reason is because some cells in our immune system ...

Erica Campbell chose a mastectomy. That choice gave her power — and helped her make peace with her biggest regret.

Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting. Share. CHICAGO--(BUSINESS WIRE) ...

ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. PR Newswire. HOUSTON, May 30, 2025.